Skip to main content
. Author manuscript; available in PMC: 2019 Jun 14.
Published in final edited form as: J Med Chem. 2018 May 24;61(11):4946–4960. doi: 10.1021/acs.jmedchem.8b00419

Table 1.

IC50 values for inhibition of CYP17A1-mediated progesterone 17α-hydroxylation and CYP21A2-mediated progesterone 21-hydroxylation by abiraterone and its analogs

entry Inhibitor Modification CYP17A1 IC50 ± S.E. (nM) CYP21A2 IC50 ± S.E. (nM) CYP21A2 IC50 CYP17A1 IC50
1 Abiraterone (1b) 4.94 ± 0.09 32.4 ± 2.5 6.6
2 Galeterone 28.1 ± 2.3 77.2 ± 8.9 2.7
3 3b 17-phenyl >20,000 ≥ 700
4 4 Δ4 6.13 ± 0.41 0.70 ± 0.03 0.11
5 6b 5α,6α-epoxide 7.83 ± 0.92 42.1 ± 8.5 5.4
6 7 Δ4, C-6 CN 15.5 ± 2.7 23.9 ± 3.8 1.5
7 8 Δ4, C-6 CONH2 22.8 ± 1.5 673 ± 90 29
8 10b 5α-H, 6α-OH 7.2 ± 0.32 234 ± 32 33
9 12b 5α-H, 6-oxo 12.4 ± 0.49 440 ± 60 35
10 13b 5α-H, 6-oxime 16.5 ± 2.5 1390 ± 120 84
11 14b B-ring expanded lactam 230 ± 51 3605 ± 1740 16